CA2827072C - Diaminopyrimidine derivatives and processes for the preparation thereof - Google Patents

Diaminopyrimidine derivatives and processes for the preparation thereof Download PDF

Info

Publication number
CA2827072C
CA2827072C CA2827072A CA2827072A CA2827072C CA 2827072 C CA2827072 C CA 2827072C CA 2827072 A CA2827072 A CA 2827072A CA 2827072 A CA2827072 A CA 2827072A CA 2827072 C CA2827072 C CA 2827072C
Authority
CA
Canada
Prior art keywords
propylpyrimidin
group
piperidin
amine
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2827072A
Other languages
English (en)
French (fr)
Other versions
CA2827072A1 (en
Inventor
Hyun-Joo Lee
Dong-Hoon Kim
Tae-Kyun Kim
Young-Ae Yoon
Jae-Young Sim
Myung-Hun Cha
Eun-Jung Jung
Kyoung-Kyu AHN
Tai-Au Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuhan Corp
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of CA2827072A1 publication Critical patent/CA2827072A1/en
Application granted granted Critical
Publication of CA2827072C publication Critical patent/CA2827072C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2827072A 2011-02-25 2012-02-24 Diaminopyrimidine derivatives and processes for the preparation thereof Active CA2827072C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20110016981 2011-02-25
KR10-2011-0016981 2011-02-25
PCT/KR2012/001423 WO2012115478A2 (en) 2011-02-25 2012-02-24 Diaminopyrimidine derivatives and processes for the preparation thereof

Publications (2)

Publication Number Publication Date
CA2827072A1 CA2827072A1 (en) 2012-08-30
CA2827072C true CA2827072C (en) 2019-01-08

Family

ID=46721361

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2827030A Active CA2827030C (en) 2011-02-25 2012-02-24 Diaminopyrimidine derivatives and processes for the preparation thereof
CA2827072A Active CA2827072C (en) 2011-02-25 2012-02-24 Diaminopyrimidine derivatives and processes for the preparation thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2827030A Active CA2827030C (en) 2011-02-25 2012-02-24 Diaminopyrimidine derivatives and processes for the preparation thereof

Country Status (17)

Country Link
US (4) US9890138B2 (enExample)
EP (2) EP2678331B1 (enExample)
JP (2) JP5890436B2 (enExample)
KR (2) KR101671341B1 (enExample)
CN (2) CN103391935B (enExample)
AU (2) AU2012221925B2 (enExample)
BR (2) BR112013019942B1 (enExample)
CA (2) CA2827030C (enExample)
DK (1) DK2678332T3 (enExample)
ES (2) ES2587304T3 (enExample)
HU (1) HUE029988T2 (enExample)
IN (1) IN2013MN01519A (enExample)
MX (2) MX336155B (enExample)
PL (2) PL2678332T3 (enExample)
PT (1) PT2678332T (enExample)
RU (1) RU2587493C2 (enExample)
WO (2) WO2012115480A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2013MN01519A (enExample) * 2011-02-25 2015-06-12 Yuhan Corp
TWI623531B (zh) 2012-11-21 2018-05-11 Ptc治療公司 經取代反向嘧啶bmi-1抑制劑
KR101657616B1 (ko) * 2013-05-24 2016-09-19 주식회사유한양행 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법
JP6524094B2 (ja) * 2013-08-30 2019-06-05 ピーティーシー セラピューティクス, インコーポレイテッド 置換ピリミジンBmi−1阻害剤
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
CN104003944B (zh) * 2014-05-29 2016-08-24 西北师范大学 一种嘧菌胺的制备方法
KR102073854B1 (ko) * 2014-10-13 2020-02-05 주식회사유한양행 Egfr 돌연변이 키나아제 활성을 조절하기 위한 화합물 및 조성물
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
CN105646321A (zh) * 2016-01-07 2016-06-08 中国药科大学 (s)-3-羟基吡咯烷盐酸盐的制备方法
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
KR102441327B1 (ko) 2018-05-18 2022-09-07 주식회사유한양행 다이아미노피리미딘 유도체 또는 이의 산부가염의 신규의 제조방법
US12023335B2 (en) 2018-08-17 2024-07-02 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
IL283901B2 (en) * 2018-12-18 2025-03-01 Astrazeneca Ab Process and intermediates for the preparation of 4-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-((R)-S-methylsulfonimidoyl)cyclopropyl]pyrimidin-2-yl}-1H-pyrrolo[2,3-b]pyridine
CN110317176A (zh) * 2019-07-04 2019-10-11 沈阳药科大学 2-氨基嘧啶类化合物及其用途
KR20220006776A (ko) * 2020-07-09 2022-01-18 주식회사유한양행 다이아미노피리미딘 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물 및 이의 제조방법
WO2025104079A1 (en) * 2023-11-17 2025-05-22 Helmholtz-Zentrum für Infektionsforschung GmbH Salicylic acid and picolinic acid derivatives as inhibitors of energy coupling factor (ecf) transporters for the treatment of bacterial infections

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4870074A (en) 1986-04-30 1989-09-26 Dainippon Pharmaceutical Co., Ltd. Substituted benzamide derivatives, for enhancing gastrointestinal motility
GB9005014D0 (en) 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
KR960704855A (ko) * 1993-10-12 1996-10-09 돈 엠. 커. 1n-알킬-n-아릴피리미딘아민 및 이들의 유도체 (1n-alkyl-n-arylpyrimidinamines and derivatives thereof)
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
IL112024A (en) 1993-12-21 1999-07-14 Novo Nordisk As Pharmaceutical compositions comprising tetrahydropyridine derivatives substituted with oxadiazole or thiadiazole for treating gastrointestinal motility disorders
CN1102144C (zh) * 1994-08-13 2003-02-26 株式会社柳韩洋行 新的嘧啶衍生物及其制备方法
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
IN188411B (enExample) * 1997-03-27 2002-09-21 Yuhan Corp
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
JP2007500683A (ja) * 2003-07-25 2007-01-18 チバ スペシャルティ ケミカルズ ホールディング インコーポレーテッド 抗菌剤としての、置換された2,4−ビス(アルキルアミノ)ピリミジン又は−キナゾリンの使用
KR20060118421A (ko) * 2003-08-29 2006-11-23 다이노젠 파마세우티컬스, 인코포레이티드 위장 운동 장애의 치료에 유용한 조성물
US20060057972A1 (en) 2004-09-14 2006-03-16 Wikel Harold L Adapter for a modular wireless communication device
US20060128726A1 (en) 2004-11-24 2006-06-15 Xuebao Wang Process for preparing novel crystalline forms of (2S)-1-[[(7R)-7-(3,4-dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5]pyrimidine-6-yl]carbonyl]-2-(4-fluorophenyl)pyrrolidine, novel stable forms produced therein and formulations
EP1856114B1 (en) 2005-02-25 2014-08-20 Pfizer Inc. Benzisoxazole derivatives
US20070032514A1 (en) 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
WO2007062417A1 (en) * 2005-11-28 2007-05-31 Kalypsys, Inc. Methods of preparing 2-imidazol-1-yl-4-methyl-6-pyrrolidin-2-yl-pyrimidine and 4-(1-alkylpyrrolidin-2-yl)-2-(1h-imidazol-1-yl)-6-methylpyrimidine derivatives
WO2007114323A1 (ja) * 2006-04-04 2007-10-11 Taisho Pharmaceutical Co., Ltd. アミノピロリジン化合物
US20090306067A1 (en) 2006-04-10 2009-12-10 Harald Engelhardt 2, 4-diaminopyrimidide derivates and their use for the treatment of cancer
MX2010008700A (es) * 2008-02-22 2010-08-30 Hoffmann La Roche Moduladores de beta-amiloide.
JP5918693B2 (ja) * 2009-05-05 2016-05-18 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Egfr阻害剤及び疾患の治療方法
IN2013MN01519A (enExample) * 2011-02-25 2015-06-12 Yuhan Corp

Also Published As

Publication number Publication date
US20150274700A2 (en) 2015-10-01
KR101671341B1 (ko) 2016-11-01
KR20120098483A (ko) 2012-09-05
EP2678332A4 (en) 2014-07-23
WO2012115478A2 (en) 2012-08-30
JP2014506592A (ja) 2014-03-17
US20180111918A1 (en) 2018-04-26
KR101671348B1 (ko) 2016-11-01
US10227330B2 (en) 2019-03-12
CN103402997A (zh) 2013-11-20
PL2678331T3 (pl) 2016-12-30
CA2827072A1 (en) 2012-08-30
AU2012221927B2 (en) 2016-04-28
US9890138B2 (en) 2018-02-13
HUE029988T2 (en) 2017-04-28
ES2579830T3 (es) 2016-08-17
WO2012115480A2 (en) 2012-08-30
CN103391935A (zh) 2013-11-13
JP2014506591A (ja) 2014-03-17
MX2013009627A (es) 2014-02-17
BR112013020641A2 (pt) 2016-10-18
EP2678331B1 (en) 2016-04-27
DK2678332T3 (en) 2016-08-15
MX336155B (es) 2016-01-07
JP5980236B2 (ja) 2016-08-31
CN103391935B (zh) 2015-12-23
CA2827030C (en) 2019-01-08
CA2827030A1 (en) 2012-08-30
AU2012221925B2 (en) 2016-05-05
US20180072705A1 (en) 2018-03-15
US20130331377A1 (en) 2013-12-12
KR20120098484A (ko) 2012-09-05
MX337477B (es) 2016-03-07
RU2013142188A (ru) 2015-03-27
EP2678331A4 (en) 2014-07-30
WO2012115478A3 (en) 2012-10-18
HK1188214A1 (zh) 2014-04-25
JP5890436B2 (ja) 2016-03-22
US20130338179A1 (en) 2013-12-19
WO2012115480A3 (en) 2012-10-18
BR112013019942B1 (pt) 2022-01-11
EP2678331A2 (en) 2014-01-01
CN103402997B (zh) 2015-08-26
EP2678332A2 (en) 2014-01-01
BR112013019942A2 (pt) 2018-08-14
RU2013142187A (ru) 2015-03-27
BR112013020641B1 (pt) 2021-11-03
RU2587493C2 (ru) 2016-06-20
ES2587304T3 (es) 2016-10-21
US9850227B2 (en) 2017-12-26
IN2013MN01519A (enExample) 2015-06-12
PL2678332T3 (pl) 2016-12-30
PT2678332T (pt) 2016-08-22
US10640490B2 (en) 2020-05-05
MX2013009549A (es) 2013-09-06
HK1188215A1 (en) 2014-04-25
EP2678332B1 (en) 2016-05-18

Similar Documents

Publication Publication Date Title
CA2827072C (en) Diaminopyrimidine derivatives and processes for the preparation thereof
AU2008309517B2 (en) Inhibitors of protein kinases
KR20210040368A (ko) 사이클린 의존성 키나제의 억제제
TWI450893B (zh) Inhibition of prostaglandin D synthase in the piper Compounds
KR20120114355A (ko) 화합물 및 방법
KR20170018913A (ko) 리신 특이적 데메틸라제-1의 억제제
CA2731196A1 (en) Benzazepine derivatives and their use as hstamine h3 antagonists
JPWO2013005755A1 (ja) メチルピペリジン誘導体
JP2014141480A (ja) メチルピペリジン誘導体を含有する医薬
RU2587981C2 (ru) Производные диаминопиримидина и способы их получения
HK1188214B (en) Diaminopyrimidine derivatives and processes for the preparation thereof
JP2016520098A (ja) ピリミジン環を含む二環式誘導体及びその製造方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170222